RETN and Obesity: Increasing evidence from clinical studies suggests that resistin is implicated in various human pathologies, including MetS, type 2 diabetes, cardiovascular disease [CVD], and obesity-related subclinical inflammation [13–16], but the role of resistin in the development of NAFLD is controversial.